Send
Print
Norbert Nagel
Pfizer declared it will purchase all Metsera shares for $47.50 in cash. This signifies a premium of roughly 42.5% above Friday's closing price.
Pfizer is also ready to pay an extra $22.50 for each share if Metsera reaches specific milestones, such as starting late-stage trials and securing regulatory approvals for its medications.
This might appraise Metsera at as much as $7.3 billion.
The transaction, pending the acquisition of required approvals and regulatory authorizations, is anticipated to conclude in the fourth quarter of 2025.
Metsera was established in 2022 and is based in New York City. The organization is creating solutions for obesity. Initial tests of her medication, MET-233i, revealed that it assists patients in shedding as much as 8.4% of their body weight within 36 days.
source: bloomberg.com
Pfizer is also ready to pay an extra $22.50 for each share if Metsera reaches specific milestones, such as starting late-stage trials and securing regulatory approvals for its medications.
This might appraise Metsera at as much as $7.3 billion.
The transaction, pending the acquisition of required approvals and regulatory authorizations, is anticipated to conclude in the fourth quarter of 2025.
Metsera was established in 2022 and is based in New York City. The organization is creating solutions for obesity. Initial tests of her medication, MET-233i, revealed that it assists patients in shedding as much as 8.4% of their body weight within 36 days.
source: bloomberg.com
